Zevra Therapeutics, Inc. (ZVRA)
NASDAQ: ZVRA · Real-Time Price · USD
11.65
-0.40 (-3.32%)
Sep 15, 2026, 4:00 PM EDT - Market closed
Zevra Therapeutics Ratios and Metrics
Market cap in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 15, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 692 | 504 | 445 | 272 | 158 | 308 | |
Market Cap Growth | 59.04% | 13.31% | 63.82% | 71.57% | -48.52% | 536.60% |
Enterprise Value | 472 | 368 | 416 | 233 | 97 | 178 |
Last Close Price | 11.65 | 8.96 | 8.34 | 6.55 | 4.59 | 8.71 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 15, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 12.13 | 6.50 | - | - | - | - |
Forward PE | 13.65 | 19.15 | 102.50 | 102.50 | 102.50 | 24.17 |
PS Ratio | 5.08 | 4.74 | 18.85 | 9.90 | 15.59 | 10.74 |
PB Ratio | 3.18 | 3.26 | 11.22 | 4.39 | 2.11 | 2.42 |
P/TBV Ratio | 3.34 | 3.51 | - | - | 2.11 | 2.42 |
P/FCF Ratio | 21.21 | - | - | - | - | 29.76 |
P/OCF Ratio | 20.71 | - | - | - | - | 29.47 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 15, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 3.47 | 3.45 | 17.61 | 8.49 | 9.52 | 6.21 |
EV/EBITDA Ratio | 11.63 | - | - | - | - | 22.27 |
EV/EBIT Ratio | 12.08 | - | - | - | - | 23.01 |
EV/FCF Ratio | 14.46 | - | - | - | - | 17.20 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 15, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.01 | 0.41 | 1.52 | 0.71 | 0.19 | 0.01 |
Debt / EBITDA Ratio | 0.04 | 92.54 | - | - | - | 0.18 |
Debt / FCF Ratio | 0.05 | - | - | - | - | 0.16 |
Net Debt / Equity Ratio | -1.01 | -0.83 | -0.23 | -0.39 | -0.91 | -0.87 |
Net Debt / EBITDA Ratio | -5.43 | 713.99 | 0.11 | 0.49 | 2.87 | -13.87 |
Net Debt / FCF Ratio | -6.75 | 52.53 | 0.13 | 0.71 | 3.65 | -10.71 |
Asset Turnover | 0.49 | 0.46 | 0.14 | 0.19 | 0.08 | 0.40 |
Inventory Turnover | 3.48 | 8.89 | - | - | - | - |
Quick Ratio | 5.02 | 5.46 | 2.35 | 1.16 | 7.58 | 26.92 |
Current Ratio | 5.17 | 5.68 | 2.53 | 1.18 | 7.72 | 27.20 |
Return on Equity (ROE) | 34.80% | 85.66% | -207.84% | -67.23% | -26.48% | -28.18% |
Return on Assets (ROA) | 8.74% | -1.14% | -31.03% | -21.55% | -12.54% | 6.70% |
Return on Invested Capital (ROIC) | 1679.05% | -14.18% | -254.55% | -223.98% | -218.60% | 77.08% |
Return on Capital Employed (ROCE) | 15.40% | -1.70% | -60.40% | -50.30% | -24.10% | 6.00% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 15, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 8.27% | 16.50% | -23.70% | -16.95% | -16.90% | -2.78% |
FCF Yield | 4.72% | -0.48% | -15.65% | -12.45% | -11.88% | 3.36% |
Buyback Yield / Dilution | -13.46% | -23.81% | -30.46% | -2.79% | -15.87% | -647.72% |